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Background: Besides its classical role in musculoskeletal diseases, vitamin D deficiency has recently been found to
be associated with cardiometabolic risks such as hypertension, diabetes mellitus and hypercholesterolemia.
Although Malaysia is a sunshine-abundant country, recent studies found that vitamin D deficiency prevalence was
significantly high. However, few published studies that measured its effect on cardiometabolic risk factors were
found in Malaysia. There are also limited clinical trials carried out globally that tried to establish the causality of
vitamin D and cardiometabolic risks. Therefore, a double blind, parallel, randomized controlled trial on vitamin D
and cardiometabolic risks is planned to be carried out.
The objective of this study is to investigate whether vitamin D supplements can reduce the cardiometabolic risk
and improve the quality of life in urban premenopausal women with vitamin D deficiency.
Methods/design: Three hundred and twenty premenopausal women working in a public university in Kuala
Lumpur, Malaysia will be randomized to receive either vitamin D supplement (50,000 IU weekly for 8 weeks and
50,000 IU monthly for 10 months) or placebo for 12 months. At baseline, all participants are vitamin D deficient
(≤ 20 ng/ml or 50 nmol/l). Both participants and researchers will be blinded. The serum vitamin D levels of all
participants collected at various time points will only be analysed at the end of the trial. Outcome measures such as
25(OH) D3, HOMA-IR, blood pressure, full lipid profiles will be taken at baseline, 6 months and 12 months. Health
related quality of life will be measured at baseline and 12 months. The placebo group will be given delayed
treatment for six months after the trial.
Discussion: This trial will be the first study investigating the effect of vitamin D supplements on both the
cardiometabolic risk and quality of life among urban premenopausal women in Malaysia. Our findings will
contribute to the growing body of knowledge in the role of vitamin D supplements in the primary prevention for
cardiometabolic disease.
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Vitamin D or also known as the “sunshine vitamin” is a
fat-soluble vitamin that is associated with bone health. It
is well recognized that vitamin D deficiency leads to rick-
ets in children and osteomalacia and osteoporosis in
adults [1]. However, recent findings have recognized un-
known roles of vitamin D such as in the renin production
in the kidney [2-4], insulin production in the pancreas
[5-7], production of cathelecidin in macrophages [8,9]
and growth and proliferation of both vascular smooth
muscle cells and cardiomyocytes [7]. With these brand
new discoveries, vitamin D maybe be associated with dis-
eases such as hypertension, diabetes mellitus, hyperlipi-
demia and cardiovascular diseases [1,9-11].
A few observational studies have shown significant in-
verse correlation between blood pressure and renin-
angiotensin activity [2,12-15]. An observational study in
Korea also found a strong inverse association of vitamin
D and hypertension [16].
Low serum vitamin D level has been proven to be
inversely correlated with type 2 diabetes mellitus. It is
known that normal insulin secretion in pancreatic ß-cells
depends on vitamin D. A reduction in vitamin D level can
result in an increase in insulin resistance and reduction in
insulin secretion [2,6,9]. The prevalence of type 2 diabetes
mellitus among South Asian origin women living in New
Zealand with lower serum Vitamin D is three times
higher than the New Zealand national incidence for dia-
betes [16].
Other mechanisms by which vitamin D may protect
against cardiovascular disease is through decreased levels
of triglycerides and low-density lipoprotein cholesterol.
This is possible as vitamin D increases the lipoprotein li-
pase activity in adipocytes [17]. In addition, improving vita-
min D levels will reduce the risk of developing type 2
diabetes mellitus and this will further reduce the lipopro-
tein disorders thus reducing the risk of cardiovascular dis-
eases [18].
With these new discoveries, vitamin D deficiency
could be considered as a new modifiable risk factor for
cardiometabolic disease; however, this needs more per-
suasive evidence. Many observational studies indicate
the association between vitamin D and cardiometabolic
risks [10,17,19]. However, very limited trials are available
to provide stronger evidence on the relationship between
vitamin D and cardiometabolic risks. To date, only few
clinical trials investigate cardiometabolic risks as its pri-
mary outcomes [14,16,20-23]. The results of these clinical
trials are also often inconsistent in the effects of vitamin D
supplementation on cardiometabolic risks, especially among
the small trials [14,16,17,21,24-26]. Therefore, there is a
need to determine whether treating vitamin D deficiency
using vitamin D supplements could contribute to the pre-
vention of cardiometabolic diseases.The ultra-violet B (UVB) ray from the sun is the
major and inexpensive source of vitamin D compare to
other natural sources such as food, which contains a
very small amount of vitamin D. Nevertheless; the
prevalence of vitamin D deficiency is still high globally.
In the United States, the prevalence of vitamin D defi-
ciency was 25% to 57% as reported in the Third
National Health and Nutrition Examination Survey
(NHANES III) [27], whereas the prevalence of vitamin
D deficiency was 28% in the Framingham Offspring
Cohort study [19] and 47.8% in a study in Amsterdam
[28]. This prevalence will remain elevated during the
winter seasons, especially among the elderly and home-
bound geriatric patients [29-31]. Although vitamin D
deficiency is common among people living in higher
latitude countries, surprisingly high prevalence of vita-
min D deficiency is also found in countries nearer to
the equator which supposed to get sufficient sunlight
all year round. Countries like Iran reported 61% of vita-
min D deficiency [10], 64.6% in Bangkok, Thailand [32]
and 66.3% in India [33]. These high rates of vitamin D de-
ficiency and its association with cardiometabolic diseases
suggesting an ever expanding importance of vitamin D
roles in our health and well-being.
Malaysia is located in latitude 2° 30’ N and is blessed
with sufficient sunshine all year round necessary for cu-
taneous synthesis of vitamin D. Khor et al. [34] however,
reported that almost 35.3% of primary school children in
Kuala Lumpur were vitamin D deficient, while approxi-
mately 70% of Malay adults in Kuala Lumpur were
found to have vitamin D deficiency [35]. In addition,
both studies found an inverse association between vita-
min D status and obesity. These findings raise concerns
as the prevalence of obesity in Malaysia is also on the
rise [36]. Metabolic syndrome was found to be associated
with vitamin D deficiency among Malay adults [35].
Therefore, there is a need for conclusive evidence from
randomized controlled trials (RCT) to evaluate the roles
of vitamin D in the primary prevention of cardiometabolic
risks.
Therefore, we proposed to start a RCT with the follow-
ing objectives:
i. To investigate whether vitamin D supplements can
improve cardiometabolic risk factors such as blood
pressure (BP), homeostasis model assessment insulin
resistant (HOMA-IR), triglycerides (TG) and high-
density lipoprotein cholesterol (HDL).
ii. To investigate whether vitamin D supplements can
improve the vitamin D status of urban
premenopausal women who are vitamin D
deficient.
iii. To investigate whether vitamin D supplements can
improve the health-related quality of life.
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Study design
This is a double-blind, randomized placebo-control, par-
allel trial in which the participants will be randomized
into 1:1 ratio.Setting
This study will be conducted at a public university in
Kuala Lumpur, Malaysia. Kuala Lumpur is located near
the equator at latitude 03° 09’N.Participants
All premenopausal women working in the public univer-
sity will be invited for screening for their eligibility.Inclusion/exclusion criteria
All premenopausal women aged 30 years old and above
with vitamin D deficiency; serum 25(OH)D level ≤ 20 ng/ml
(or ≤ 50 nmol/l), will be invited to participate in this study.
Premenopausal women are included as they will be at a
lower risk for osteoporosis than post-menopausal women
if they are vitamin D deficient.
Those with an abnormal level of serum parathyroid hor-
mone (PTH) (>55 pg/ml) and serum calcium (> 10.4 mg/dl),
known to have illnesses such as granuloma forming dis-
order (e.g. Tuberculosis), lymphoma, sarcoidosis or any
type of cancers will be excluded. Women taking vitamin
D supplements containing > 1000 IU/day or any forms of
calcitriol (1,25(OH)2D3) will be excluded. Pregnant
women or participants who were found to be pregnant
during the study will also be excluded from the study.Sample size estimation
According to the study by Zittermann et al. [25], partici-
pants from the intervention arm with vitamin D supple-
mentation was found to achieve a reduction in triglycerides
of 0.19 ± 0.54 mmol/L and a change in mean for LDL-
cholesterol of 0.19+1.03 mmol/L. Sample size calculation
was conducted using OpenEpi version 2.3.1 Software. With
a power of 80% and a two-sided 5% significant level, a
minimum of 88 participants per arm is required using the
results on triglycerides, while 146 participants is required
with the results on LDL-cholesterol. In order to achieve
adequate power, additions of 10% are added to 146 to ac-
count for possible attrition. Ultimately, the desired sample
size for this study is 160 participants for each arm with a
total of 320.Conduct of the study
The study will be divided into two phases: Phase I and
Phase II.Phase I
Premenopausal women who are interested to participate
will be given brief introduction regarding the trial and of-
fered for blood investigation for serum 25(OH)D, serum
calcium, fasting blood insulin, fasting blood glucose, lipid
profile and serum PTH as well as anthropometric and
blood pressure measurements. Demographic data, sun-
light exposure, physical activity and health-related quality
of life questionnaires will also be administered at this
stage. All the blood samples taken at this stage will be
analysed and participants who meet the inclusion criteria
will proceed to Phase 2.
Phase 2
Selected participants will be randomized into Vitamin D
or placebo groups. Informed consent will be obtained
from all participants at this stage. The intervention will
be given for one year, and participants will be called for
blood check at 6 months and 12 months after interven-
tion completes (Figure 1). Table 1 shows the outcome
measures and time for measurement.
Randomization
Eligible participants will be randomized into the active
and placebo arm. The randomization sequence will be
created using GraphPad Software with a 1:1 allocation by
a staff (AC) with no involvement in the trial. The partici-
pant’s names will be matched with the random number
sequence. The names of participants from intervention
and placebo will be printed and pasted on to the tubes
filled with either vitamin D powder or placebo. The tubes
used will be identical for both active intervention and pla-
cebo, and allocation sequence data will be kept by AC in
a secure place so that it cannot be accessed or influenced
by anyone, including the researchers.
Vitamin D intervention
The intervention consists of 50,000 IU of cholecalciferol
(25(OH)D3) supplements with an average weight of 0.5
gram in the form of powder. The vitamin D supplements
are purchased from DSM Nutritional products Ltd,
Switzerland. Vitamin D supplement will be taken orally
by the participants by diluting the powder into warm
water before consumption. The consumption frequency
will be once a week for 8 weeks (equivalent to 7142 IU/
day) and then once a month for maintenance for 10
months (equivalent to 1667 IU/day). The consumption
of 50,000 IU of vitamin D per week or per month, is
considered to be safe as the tolerable upper intake level
for vitamin D is 10,000 IU per day [37].
The placebo will be identical in taste, texture and
colour with the active supplements and will be given the
same manner of the active supplement. The vitamin D
supplement and placebo will be packed by the Pharmacy
Se 25(OH)D, Se Ca, 
Se PTH, Lipid 
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Figure 1 Recruitment flow chart.
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(UMMC). Both the active supplements and placebo will
be given to participants in a translucent pill container
with only their names on the label. Labelling of the con-
tainers will be done by the same person (AC) doing the
randomization and allocation sequence. The serum Vita-
min D collected at different time points will only be
analysed at the end of the trial. This will enable both the
researchers and participants to be remained blinded
throughout the trial.
To ensure compliance with the intervention, reminders
about the intervention appointments will be sent regu-
larly via phone messages, email or phone calls. For those
who do not attend the intervention appointment, the re-
searcher will visit them at their workplace to give them
the active supplements or placebo personally.
Blood sampling and methods of analysis
Venous blood samples will be taken by registered staff
nurses using a sterile vacutainer needle and needle
holder between 7.30 am and 9.30 am. All the partici-
pants will be asked to fast overnight for at least 8 hours
before blood taking procedure. Blood serum will be used
for the analysis of calcium (Ca), PTH, 25(OH)D3, fasting
blood insulin and lipid profiles. The blood samples will
be allowed clotting for about 30 minutes and centrifugedfor 10 minutes at 2000 G at 4°C within 2 hours. All the
blood serum will be stored at −80°C whilst waiting for
analysis. Analysis of fasting blood glucose will be using
blood plasma. Homeostasis model assessment of insulin
resistance (HOMA-IR) will be used to evaluate insulin
resistance. It can be calculated from a simple linear
equation based on pairing FBS and Fasting Blood Insulin
to establish a measure for insulin resistant: HOMA-IR =
FBS (mmol/L) X Fasting Blood Insulin (IU per ml)/22.5.
Radioimmunoassay analysis method (DiaSorin, Stillwater,
MN) will be used to measure serum 25(OH)D. All tests
and analysis will be carried out by the Clinical Diagnostic
Laboratory, University Malaya Medical Centre.
Anthropometry and blood pressure measurement
Blood pressure will be measured twice using a digital
sphygmomanometer (OMRON HEM-907 model) in sit-
ting position. The average of two measurements will be
taken.
Measurement such as weight and height will be mea-
sured using calibrated digital weighing scales (Seca 808,
Germany) and stadiometer (Seca, Germany) respective-
ly. Body Mass Index (BMI) will be calculated from the
formula of weight (kg)/height2(meters). Waist circumfer-
ence will be measured using circumference measure-
ment tape from the point midway between the iliac crest




Serum 25(OH)D x x x
Serum calcium x x x
Serum PTH x x x
Fasting blood glucose x x x
Fasting blood insulin x x x
Total cholesterol x x x
Triglycerides x x x
HDL-C x x x
LDL-C x x x
Anthropometry and clinical assessments
Height, weight, BMI x x x
Blood pressure x x x
Waist circumference x x x
Questionnaires
Sociodemographics x
Medical and family history x
Dietary assessment x x
SF36 version 2 x x
Sunlight exposure history x x
IPAQ x x
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Questionnaires administration
The questionnaires will contain two parts. Part 1 of the
questionnaire enquires on socio demographic data, sun-
light exposures, physical activity (International Physical
Activity Questionnaires – IPAQ) and health-related
quality of life questions (SF36® version 2 questionnaires).
This questionnaire will be completed by participants at
baseline.
The sunlight exposure questions will cover on history
of sunlight exposure such as duration of outdoor activity
in minutes per day as well as sunlight avoidance history
such as usage of umbrella and sun block lotion. Partici-
pants are also enquired about their clothing style such
as wearing long sleeves and hijab or veil. This question-
naire is obtained from a previous study done at the same
setting [35].
The International Physical Activity Questionnaire (IPAQ)
will be used to assess the physical activity patterns. It is a
self-administered, 7-day period of IPAQ long form. We
are using Malay version of IPAQ (IPAQ-M) and English
version of IPAQ for the convenience of our participants
in which they can choose to either answer the Malay orEnglish version. IPAQ-M has been validated for use in
Malaysian population [38].
SF-36W version 2 health survey will be used to assess
participant’s health-related quality of life on physical and
emotional wellbeing for participants with vitamin D de-
ficiency and to assess if any improvements of health-
related quality of life after intervention. Permission for
usage of this questionnaire will be purchased from
QualityMetric’s SF™. This health survey asks 36 ques-
tions measuring the functional health and well-being
from participant’s point of view. It is a practical, reliable,
and valid measure of physical and mental health. The
SF-36 version 2 health survey will provide scores for
each of the eight health domains, including the physical
functioning, role-physical, bodily pain, general health,
vitality, social functioning, role emotional and mental
health together with psychometrically-based physical
component summary (PCS) and mental component
summary (MCS). The QualityMetric’s SF™ smart meas-
urement system will be used to automatically calculate
the scores. These questionnaires are available in Malay
and English version, and it has been validated for use in
Malaysian population by Sararaks et al. [39]. This ques-
tionnaire will be administered during screening stage
and again at the end of the trial to see if there are any
changes in quality of life after the intervention.
Second part of the questionnaire contains a 7-day diet-
ary diary. Participants will be asked to give a detailed de-
scription of foods eaten and to estimate the amounts
using natural or household measures (e.g. pieces, cups).
An experienced dietitian will give instruction on how to
fill in the diary. A list of instruction will also be provided
in the diary booklet including examples. The dietitian will
then convert the estimated amounts using a standardised
protocol into weights as well as checking the complete-
ness of the diary prior to data entry into The Nutritionist
Pro software. Additional new foods and recipes will be
added as required. Vitamin D composition in food will be
obtained from The Nutritionist Pro™ Diet Analysis soft-
ware (Axxya System LLC). After data entry, each record
will be verified by a nutrition researcher and corrections
will be made if any errors in data entry are found. All vol-
unteers will be given a pre-addressed envelope for the re-
turn of the diary to the researcher within 2 weeks upon
completion.Provision of results to participants
All participants at screening stage will be informed of
their anthropometry, blood pressure measurement and
blood results. Participants who fail to come to get their
results will receive notification of all of their results to-
gether with advice about supplementation through mail
where applicable.
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of their current vitamin D status, and if they are taking
the active or placebo dose. All participants in the placebo
group will be given vitamin D supplements of 50,000 IU
per week for 8 weeks and 50,000 IU per month for 4
months upon completion of the trial. Whereas partici-
pants taking active dose will be given 50,000 IU per
month of vitamin D supplements for 3 months upon
completion of the trial.
Funding/ethics
This study was approved by the Medical Ethics Com-
mittee of University Malaya Medical Centre (reference
number 907.22). This trial is funded by the University
Malaya (Post Graduate Research Grant, PV080/2012A
and University Malaya Research Grant, RG051/09HTM).
Data handling and statistical analysis
We will use Microsoft Access to maintain the demo-
graphic data. To record the progress of each participant
throughout the trial period, we will use a check box to
allow for easy access and follow-up purposes. Raw data
obtain from the questionnaire and blood results will be
entered into SPSS software version 16.0 (SPSS Inc., 2009,
Chicago, Illinois). The data will be cleaned and checked
for coding errors. Preferably, data will be double-entered
to check for duplication and outliers before commence-
ment of statistical analysis.
For baseline characteristics, descriptive statistics will
be used. Categorical data will be described using count,
percentages and 95% confidence intervals when applic-
able. Exact test on proportions will be used to compare
categorical variables since this is a comparative trial data.
All numerical data will be checked for normality. For
normally distributed data, mean with standard deviation,
independent t-test will be used and analyse using SPSS
16.0. However, if the data is found to be non-normally
distributed or have un-equal variances, exact (permuta-
tion) tests will be used. Exact tests analyses will be
undertaken using StatXact® 9 (Cytel Inc.).
The primary analysis will be performed to explore inter-
vention’s effects on HOMA-IR, LDL-cholesterol, TG, HDL
and BP These analyses will be following the “intention-to-
treat” principle in the comparison between the interven-
tion and the placebo group at 6 months and 12 months.
Additionally secondary analyses will be a comparison of
change of the vitamin D status and health-related quality
of life. Level of statistical significance is preset at p < 0.05.
Discussion
As suggested by M.F Holick [40], our study provides a
dose of 50,000 IU weekly for 8 weeks and followed by
50,000 IU monthly for maintenance. This is to raise the
blood level of 25(OH)D consistently above 30 ng/ml. Itis coherent as suggested by the 2011 Endocrine Society
Clinical Practice Guideline where they recommended that
for adults aged 19 – 70 years, they require at least 1500 –
2000 IU/d of supplemental vitamin D. This method will
be less costly, more convenient and will ensure compli-
ance towards treatment than daily treatment.
The main purpose of this study is to evaluate the role of
vitamin D supplements as the primary prevention meas-
ure for cardiometabolic risks. We hope to provide guid-
ance for the general population, especially to people at
risk such as elderly and women wearing hijab or veil to
improve their vitamin D status by dietary intake or vita-
min D supplements other than sunlight exposure. This
study also will provide more evidence on the relationship
between vitamin D and cardiometabolic risk. These re-
sults may be used to guide policy making decision in vita-
min D supplementation or fortification for the public. It
is well known that vitamin D intake improves individuals’
physical wellbeing. However, there is lacked of informa-
tion on whether adequate vitamin D intake will improve
mood and mental wellbeing as well. The relative question
of whether vitamin D has a greater effect on quality of life
need to be answered using clinical trials. We hope our re-
sults may answer these questions.
Trial status
Upon submission, this study is in the process of partici-
pant’s recruitment.
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